Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism
The two purposes of this study are
to determine what effect the chronic and moderate/heavy drinking of alcoholic beverages has
- on the blood level of bupropion and chlorzoxazone and their major breakdown products in the blood and
- on the stimulant effect of bupropion and
to determine what effect a normal and common (25% frequency) genetic variation of a specific liver enzyme (that breaks down bupropion) has
- on the blood levels of bupropion and its major breakdown products in the blood and
- on the stimulant effect of bupropion.
Two groups of volunteers will be recruited for this study:
- volunteers who drink moderate to heavy amounts of alcohol frequently and
- volunteers who usually do not drink alcohol.
Volunteers will NOT be asked to change their drinking (or nondrinking) habits during the study.
|Alcohol Drinking Depression Smoking Cessation Attention Deficit Disorder||Drug: Bupropion Drug: Chlorzoxazone Drug: Ethanol|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Human CYP2B6: Induction by Ethanol and Polymorphisms|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00330434
|United States, Massachusetts|
|Tufts University School of Medicine|
|Boston, Massachusetts, United States, 02111|
|Principal Investigator:||David J. Greenblatt, MD||Tufts University; Chair of Department of Pharmacology and Experimental Therapeutics, Sackler School|
|Principal Investigator:||Michael H. Court, BVsc, PhD||Tufts University, Department of Pharmacology and Experimental Therapeutics, Sackler School|